Overnight Market report, page-1552

I think Immutep will fund this phase 2 part of the thing alone and then phase 3 will be for a BP to step in either aquire the whole thing or a partnership deal with cash injected.

Even they said the biological optimum dosage (BOD) can be up to 15months to determine, I don't think this will be that long. With the adverse effects, it will be more like 3months to determine and the efficacy for confirming whether 90mg is superior to 30mg, my guess is around 6months or even less. When you look back to the AIPAC study, just at about 6months time, the patients got very responding separation between treatment and placebo. Also they mPFS for treatment/placebo groups were 7.16 and 6.7 months, respectively. By the end, the ORR for treatment group was around 48%.
So all evidence for 30mg treatment is pointing to the 6months mark. With 90mg applied now, this could be speeded up. We will see.

As you see the clarification on the trial record they just have updated, they will start the phase 3 part by the completetion of BOD. And the BOD lead in is only minium of 6 patients (3+3), should be very fast. By that stage, we should be standing on the late readout of TACTI003 (registrational readout) and completion of TACTI002 plus finalised designed of Phase 3 lung cancer trial. At that point, very sweet for someone to pay the whole thing?